FindTrial
Sign In

Induction Mortality Risk Score in Acute Myeloid Leukemia

Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study - HCC pRISM-S (HCC RISk Mortality Score)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/07/026450
Enrollment
300
Registered
2020-07-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C920- Acute myeloblastic leukemia

Interventions

Intervention1: Nil : It is an observational study Intervention2: NIL: Given study is observational, Control Intervention1: Nil: It is an observational study Control Intervention2: NIL: Given study is

Sponsors

Hematological Cancer Consortium
Lead Sponsor
Hematological Cancer Consortium
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All newly diagnosed and treated cases of acute myeloid leukemia (with either intensive induction chemotherapy or less intensive therapy)

Exclusion criteria

Exclusion criteria: Relapsed AML

Design outcomes

Primary

MeasureTime frame
Induction mortality - death due to any cause within 28 days of starting induction chemotherapyTimepoint: within 28 days of starting induction chemotherapy—

Secondary

MeasureTime frame
Event free survivalTimepoint: 3 years;Notable adverse event during induction course (defined by ICU admission, inotrope use or ventilator requirement for 24 hours)Timepoint: within 28 days of starting induction chemotherapy;Overall survivalTimepoint: 3 years—

Countries

India

Contacts

Public ContactRajan Kapoor

Jawaharlal Institute of Postgraduate Medical Education and Research

kayalsmita@gmail.com7598118439

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026